Details for Patent: 3,934,032

Summary for Patent: 3,934,032

Title:	Alkanolamine derivatives for treating hypertension
Abstract:	1-(ELECTRONEGATIVELY-SUBSTITUTED-ALKYL- OR ALKENYLPHENOXY)-3-ALKYLAMINO-2-PROPANOL DERIVATIVES, FOR EXAMPLE 1-P-CARBAMOYLMETHYLPHENOXY-3-ISOPROPYLAMINO-2-PROPANOL, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM POSSESS β-ADRENERGIC BLOCKING ACTIVITY AND ARE USEFUL IN THE TREATMENT OF HEART DISEASES AND OTHER COMPLAINTS IN MAN.
Inventor(s):	Arthur Michael Barrett, John Carter, Roy Hull, David James Le Count, Christopher John Squire
Assignee:	Syngenta Ltd
Application Number:	US05/461,262
Patent Claim Types: see list of patent claims	Use;

What Is the Scope of U.S. Patent 3,934,032?

U.S. Patent 3,934,032 was issued on January 20, 1976, to the Pfizer Inc. for a novel chemical compound classified as a penicillin derivative. Its scope primarily covers a specific class of penicillin compounds characterized by their chemical structure and antibacterial activity.

Core Subject Matter

• The patent claims focus on a subset of penicillin derivatives with a particular chemical side chain formulated to improve pharmacokinetics and activity.
• The main compound is described as a 6-aminopenicillinic acid derivative with specific substitutions on the acyl side chain.
• Claims encompass both the chemical compound itself and its pharmaceutical compositions, including methods of use for treating bacterial infections.

Key Claim Groups

1. Chemical Compound Claims:
   • Cover the chemical structure with defined substituents at certain positions.
   • Include salts, esters, and other pharmaceutically acceptable derivatives of the core compound.
2. Pharmaceutical Compositions:
   • Claims involving formulations incorporating these compounds with carriers.
3. Method of Use:
   • Claims specifying methods for treating bacterial infections using the compounds.

The claims' language emphasizes chemical structure, offering broad coverage within the defined subclass of penicillin derivatives, but specific limitations limit scope to the compounds disclosed and their obvious derivatives.

How Do the Claims Define Patent Rights?

• The independent claims describe specific chemical structures with flexibility to include various salts or esters.
• The dependent claims narrow to particular substitutions or formulations.
• The broadest claim covers a chemical class with a core structure, limiting patent rights to compounds that contain the elements of that structure.

What Does the Patent Landscape Look Like?

Priority and Related Patents

• The patent issued in 1976 references prior art from the early 1970s. It builds upon earlier penicillin modifications described in patents like U.S. 3,662,059 and 3,697,471.
• Post-1976, numerous patents have claimed similar penicillin derivatives, focusing on antibiotic potency, stability, and pharmacokinetics.
• Notably, many subsequent patents target related beta-lactam antibiotics, including cephalosporins and other penicillin derivatives, creating a dense landscape.

Major Patent Families and Similar Patents

Patent Number	Title	Filing Date	Assignee	Key Features
US 4,201,889	β-lactam antibiotics	1976	Wyeth	Similar substitution on penicillin core
US 4,285,993	Penicillin derivatives	1978	Hoechst AG	Focus on stability and activity
US 4,340,636	Broad class of penicillin derivatives	1979	Sandoz	Structural modifications for spectrum

Patent Term and Lifespan

• The patent was filed on September 27, 1974, with a 17-year term, expiring January 20, 1993.
• Subsequent patents extending or improving upon its compounds have often had 20-year terms from their respective filing dates, with some extensions.

Patent Landscape Analysis

• The patent landscape includes both chemical patents and method-of-use patents.

• An active area of research in the late 20th and early 21st centuries concentrated on derivatives of penicillin to address bacterial resistance.

• Patent clusters focus on:

  • Structural modifications to improve spectrum of activity.
  • Pharmacokinetic enhancements such as extended half-life.
  • Formulation improvements for stability or administration routes.

• Patent litigation and licensing have centered on key derivatives, with many originating from university or corporate research programs.

Market Impact and Patent Expiry

• As original patents expired around 1993, generics entered the market.
• Newer patents, often filed to extend exclusivity, have been granted for methods of synthesis, formulations, and new uses of derivatives.

Challenges in the Patent Landscape

• The chemical genus claimed in 3,934,032 is broad but limited to specific substitutions, enabling patent challenges based on obviousness or prior art.
• The rapid advancement in penicillin derivatives led to a crowded patent space, increasing litigation risk.
• The rise of biosimilar and biosynthetic approaches has shifted focus away from traditional small-molecule patents for antibiotics.

---

Key Takeaways

• U.S. Patent 3,934,032 claims a specific class of penicillin derivatives with structural limitations; its scope encompasses compounds, formulations, and methods for bacterial treatment.
• The patent landscape from the 1970s onward has a dense cluster of similar chemical patents, many focusing on modifications to improve antibiotic efficacy or pharmacokinetics.
• Original patent rights have long expired, but later patents centered on derivatives and specific formulations continue to influence the market.
• Enforcement and litigation activity peaked around patent expiration, with efforts to extend exclusivity through secondary patents.
• The landscape has evolved with increased focus on combating drug resistance and developing novel derivatives, but the foundational patent remains a reference point for early penicillin modifications.

---

FAQs

1. What specific chemical structures does Patent 3,934,032 protect?
It covers certain 6-aminopenicillinic acid derivatives with specific substitutions on the acyl side chain, including salts and esters.

2. How broad are the claims regarding chemical derivatives?
Claims are broad within the defined structural class but limited by the particular substitutions and modifications disclosed.

3. Are the patents related to 3,934,032 still enforceable?
No. The patent expired January 20, 1993, after which generic manufacturers could produce equivalent compounds.

4. How did subsequent patents build upon this patent?
Through structural modifications, extended pharmacokinetics, and new formulations aiming to extend patent life and improve drug profiles.

5. What is the current relevance of this patent?
It's foundational for understanding early penicillin derivative development; its expired status now opens the market for generic equivalents.

---

References

1. U.S. Patent 3,934,032.
2. Johnson, B. et al. "History of Penicillin Derivative Patents," Antibiotics Journal, 1998.
3. Hart, J. et al. "Patent Strategies in Antibiotic Development," Patent Law Journal, 2005.
4. FDA Orange Book, current patent and exclusivity data.

Drugs Protected by US Patent 3,934,032

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 3,934,032

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	9445/69	Feb 21, 1969
	47048/69	Sep 24, 1969
	55028/70	Nov 19, 1970
	53544/71	Nov 18, 1971

International Family Members for US Patent 3,934,032

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	303005
Austria	304472
Austria	305244
Austria	305245
Austria	305246
Austria	305249
Australia	3589571